Paul Kearney Biography and Net Worth

Data Science Advisor of Sera Prognostics

Dr. Paul Kearney serves as a Data Science Advisor to Sera Prognostics. During his tenure with the Company, including service as Chief Data Officer, he helped shape Sera’s data strategy and evidence-generation efforts. A recognized leader at the intersection of healthcare, data science, and innovation, Dr. Kearney has co-founded multiple biotechnology companies focused on oncology, pregnancy health, and food allergy, and has extensive experience in clinical research, bioinformatics, and product development. He has authored more than 100 scientific publications, is the inventor on more than 12 patents, and holds a Ph.D. from the University of Toronto.

What is Paul Kearney's net worth?: The estimated net worth of Paul Kearney is at least $339.40 thousand as of March 11th, 2026. Dr. Kearney owns 163,961 shares of Sera Prognostics stock worth more than $339,399 as of September 17th. This net worth evaluation does not reflect any other investments that Dr. Kearney may own. Learn More about Paul Kearney's net worth.
How do I contact Paul Kearney?: The corporate mailing address for Dr. Kearney and other Sera Prognostics executives is 2749 E. Parleys Way, Suite 200, Salt Lake City, UT, 84109. Sera Prognostics can also be reached via phone at 801-990-0520 and via email at [email protected]. Learn More on Paul Kearney's contact information.
Has Paul Kearney been buying or selling shares of Sera Prognostics?: Paul Kearney has not been actively trading shares of Sera Prognostics over the course of the past ninety days. Most recently, Paul Kearney sold 1,396 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $2.04, for a transaction totalling $2,847.84. Following the completion of the sale, the insider now directly owns 163,961 shares of the company's stock, valued at $334,480.44. Learn More on Paul Kearney's trading history.
Are insiders buying or selling shares of Sera Prognostics?: In the last twelve months, insiders at the sold shares 39 times. They sold a total of 167,112 shares worth more than $394,436.33. The most recent insider tranaction occured on September, 10th when insider Dyaarl Lee Jr. Anderson sold 1,800 shares worth more than $3,600.00. Insiders at Sera Prognostics own 11.3% of the company. Learn More about insider trades at Sera Prognostics.
Information on this page was last updated on 9/10/2026.

Paul Kearney Insider Trading History at Sera Prognostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2026	Sell	1,396	$2.04	$2,847.84	163,961
3/9/2026	Sell	2,026	$1.96	$3,970.96	165,357
12/10/2025	Sell	1,213	$3.31	$4,015.03	167,383
11/26/2025	Sell	1,986	$3.51	$6,970.86	168,596
9/11/2025	Sell	1,271	$3.13	$3,978.23	175,669
9/2/2025	Sell	1,458	$3.49	$5,088.42	176,940
6/10/2025	Sell	1,311	$1.48	$1,940.28	195,400
5/8/2025	Sell	7,089	$2.44	$17,297.16	196,711
3/6/2025	Sell	1,338	$4.16	$5,566.08	203,800
11/11/2024	Sell	4,078	$7.32	$29,850.96	176,889
5/15/2024	Sell	10,387	$8.24	$85,588.88	185,300
2/6/2024	Sell	4,984	$8.03	$40,021.52	160,066

Paul Kearney Buying and Selling Activity at Sera Prognostics

Sera Prognostics Company Overview

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $2.07

$2.04

$2.08

50 Day Range

MA: $2.05

$1.92

$2.27

2 Week Range

Now: $2.07

$1.56

$3.95

Volume

4,943 shs

Average Volume

48,681 shs

Market Capitalization

$81.50 million

P/E Ratio

N/A

Dividend Yield